<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098059</url>
  </required_header>
  <id_info>
    <org_study_id>CFAM810B2303</org_study_id>
    <nct_id>NCT00098059</nct_id>
  </id_info>
  <brief_title>Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection</brief_title>
  <official_title>A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herpes Simplex Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir
      in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir
      (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive
      multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess
      safety and tolerability. Part B will start only after PK data from Part A had been analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of a Single-dose of Famciclovir in Part A of the Study.</measure>
    <time_frame>8 hours and 24 hours after study drug administration (Part A)</time_frame>
    <description>A patient with multiple adverse events (AEs) within the primary system organ class is counted only once in total row.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration of Penciclovir (Cmax)</measure>
    <time_frame>plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
    <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration of Penciclovir (Tmax)</measure>
    <time_frame>Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
    <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Penciclovir Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞)</measure>
    <time_frame>Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
    <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance of Penciclovir (CL/F)</measure>
    <time_frame>Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
    <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life of Penciclovir (T1/2)</measure>
    <time_frame>Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
    <description>PK parameter; penciclovir is the active metabolite of famciclovir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Famciclovir Pediatric Oral Formulation in Part B of the Study.</measure>
    <time_frame>Administered 2 times daily over 7 days</time_frame>
    <description>A patient with multiple AEs within the primary system organ class is counted only once in total row.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Acceptability of Pediatric Oral Formulation by Patients in Part A of the Study.</measure>
    <time_frame>Day 1, after swallowing the dose.</time_frame>
    <description>Overall acceptability of the study medication was determined by caretaker response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study.</measure>
    <time_frame>Day 1 at clinic: after swallowing first dose</time_frame>
    <description>Overall acceptability of the study medication was determined by caretaker response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study</measure>
    <time_frame>Day 8 at home: after swallowing last dose</time_frame>
    <description>Overall acceptability of study medication was determined by caretaker response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>Famciclovir, pediatric oral formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famciclovir</intervention_name>
    <description>Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle</description>
    <arm_group_label>Famciclovir, pediatric oral formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History or laboratory evidence of herpes simplex infection

          -  Clinical evidence or suspicion of herpes simplex infection

        Exclusion Criteria:

          -  Patients unable to swallow

          -  Concomitant use of probenecid

          -  Positive pregnancy test

        Additional protocol-defined inclusion/exclusion criteria may apply. For detailed
        information on eligibility, please contact the study center nearest to you or call the
        following numbers: 1-862-778-3544 or 1-434-951-3228
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-3830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York at</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-3362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panama Minister of Health</name>
      <address>
        <city>Ciudad de David</city>
        <state>Chiriqui</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panama Minister of Health</name>
      <address>
        <city>Ciudad de Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Guatemala</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2004</study_first_submitted>
  <study_first_submitted_qc>December 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2004</study_first_posted>
  <results_first_submitted>February 2, 2009</results_first_submitted>
  <results_first_submitted_qc>March 20, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2009</results_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>herpes simplex</keyword>
  <keyword>cold sores</keyword>
  <keyword>fever blisters</keyword>
  <keyword>children</keyword>
  <keyword>Famvir</keyword>
  <keyword>famciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famciclovir</mesh_term>
    <mesh_term>2-Aminopurine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A (Single-dose of Famciclovir)</title>
          <description>Includes 27 patients enrolled in Part A. Two adolescent patients (13 to 18 years) were enrolled in Part A of this study under an amendment to the protocol to include adolescent aged patients. The amendment was rescinded in compliance with an FDA Pediatric Written Request and no further adolescent aged patients were enrolled.</description>
        </group>
        <group group_id="P2">
          <title>Part B (Multiple-dose of Famciclovir)</title>
          <description>Includes 47 patients enrolled in Part B. Part B started only after pharmacokinetic (PK) data from Part A had been analyzed. One patient that participated in Part A of the study also participated in Part B.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A (Single-dose of Famciclovir)</title>
          <description>Each patient in Part A received a single dose of famciclovir (12.5 mg/kg).</description>
        </group>
        <group group_id="B2">
          <title>Part B (Multiple-dose of Famciclovir)</title>
          <description>Each patient in Part B received famciclovir twice a day (b.i.d.) approximately 12 hours apart for 7 days for a total of 14 doses. An 8-step dosing scheme (ranged from 150 mg b.i.d. to 500 mg b.i.d.) was used to determine the weight-based adjusted daily dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 to &lt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 to &lt;6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to &lt;=12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 to &lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Overall Acceptability of Pediatric Oral Formulation by Patients in Part A of the Study.</title>
        <description>Overall acceptability of the study medication was determined by caretaker response.</description>
        <time_frame>Day 1, after swallowing the dose.</time_frame>
        <population>Includes all 27 patients enrolled in Part A of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;13 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;=18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Acceptability of Pediatric Oral Formulation by Patients in Part A of the Study.</title>
          <description>Overall acceptability of the study medication was determined by caretaker response.</description>
          <population>Includes all 27 patients enrolled in Part A of the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Badly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither bad nor good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Well</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study.</title>
        <description>Overall acceptability of the study medication was determined by caretaker response.</description>
        <time_frame>Day 1 at clinic: after swallowing first dose</time_frame>
        <population>Includes all 47 patients enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;13 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;=18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study.</title>
          <description>Overall acceptability of the study medication was determined by caretaker response.</description>
          <population>Includes all 47 patients enrolled in Part B of the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Badly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither bad nor good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Well</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study</title>
        <description>Overall acceptability of study medication was determined by caretaker response.</description>
        <time_frame>Day 8 at home: after swallowing last dose</time_frame>
        <population>Includes all 47 patients enrolled in Part B of the study. Response was not available for 1 patient in the 2 to &lt;6 years and 6 to &lt;=12 years groups.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;13 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;=18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study</title>
          <description>Overall acceptability of study medication was determined by caretaker response.</description>
          <population>Includes all 47 patients enrolled in Part B of the study. Response was not available for 1 patient in the 2 to &lt;6 years and 6 to &lt;=12 years groups.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Badly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither bad nor good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Well</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of a Single-dose of Famciclovir in Part A of the Study.</title>
        <description>A patient with multiple adverse events (AEs) within the primary system organ class is counted only once in total row.</description>
        <time_frame>8 hours and 24 hours after study drug administration (Part A)</time_frame>
        <population>Includes all 27 patients enrolled in Part A of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;=12 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;= 18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of a Single-dose of Famciclovir in Part A of the Study.</title>
          <description>A patient with multiple adverse events (AEs) within the primary system organ class is counted only once in total row.</description>
          <population>Includes all 27 patients enrolled in Part A of the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders and administration site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration of Penciclovir (Cmax)</title>
        <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
        <time_frame>plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
        <population>Includes all 27 patients enrolled in Part A of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;=12 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;= 18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration of Penciclovir (Cmax)</title>
          <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
          <population>Includes all 27 patients enrolled in Part A of the study.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="1.25" lower_limit="1.42" upper_limit="4.47"/>
                    <measurement group_id="O2" value="2.44" spread="0.94" lower_limit="0.42" upper_limit="3.81"/>
                    <measurement group_id="O3" value="2.82" spread="0.65" lower_limit="1.52" upper_limit="3.79"/>
                    <measurement group_id="O4" value="1.89" lower_limit="1.06" upper_limit="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Observed Plasma Concentration of Penciclovir (Tmax)</title>
        <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
        <time_frame>Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
        <population>Includes all 27 patients enrolled in Part A of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;=12 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt; =18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Plasma Concentration of Penciclovir (Tmax)</title>
          <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
          <population>Includes all 27 patients enrolled in Part A of the study.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.07" lower_limit="1.00" upper_limit="4.03"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="2.07"/>
                    <measurement group_id="O4" value="1.47" lower_limit="0.97" upper_limit="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Penciclovir Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞)</title>
        <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
        <time_frame>Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
        <population>Includes 26 of 27 patients enrolled in Part A of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;=12 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;= 18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Penciclovir Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞)</title>
          <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
          <population>Includes 26 of 27 patients enrolled in Part A of the study.</population>
          <units>(μg/mL)h</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="2.42" lower_limit="3.43" upper_limit="8.99"/>
                    <measurement group_id="O2" value="6.85" spread="1.55" lower_limit="3.19" upper_limit="9.12"/>
                    <measurement group_id="O3" value="8.15" spread="1.01" lower_limit="6.49" upper_limit="9.71"/>
                    <measurement group_id="O4" value="5.93" spread="0" lower_limit="4.84" upper_limit="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance of Penciclovir (CL/F)</title>
        <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
        <time_frame>Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
        <population>Includes 26 of 27 patients enrolled in Part A of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;=12 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;= 18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance of Penciclovir (CL/F)</title>
          <description>PK parameter; penciclovir is the active metabolite of famciclovir.</description>
          <population>Includes 26 of 27 patients enrolled in Part A of the study.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="8.5" lower_limit="11.0" upper_limit="28.8"/>
                    <measurement group_id="O2" value="25.1" spread="4.3" lower_limit="18.1" upper_limit="33.3"/>
                    <measurement group_id="O3" value="43.7" spread="9.6" lower_limit="32.4" upper_limit="60.8"/>
                    <measurement group_id="O4" value="68.8" spread="0" lower_limit="56.2" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Elimination Half-life of Penciclovir (T1/2)</title>
        <description>PK parameter; penciclovir is the active metabolite of famciclovir</description>
        <time_frame>Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose</time_frame>
        <population>Includes 26 of 27 patients enrolled in Part A of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;=12 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;= 18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-life of Penciclovir (T1/2)</title>
          <description>PK parameter; penciclovir is the active metabolite of famciclovir</description>
          <population>Includes 26 of 27 patients enrolled in Part A of the study.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.08" lower_limit="1.01" upper_limit="1.18"/>
                    <measurement group_id="O2" value="1.36" spread="0.20" lower_limit="1.10" upper_limit="1.70"/>
                    <measurement group_id="O3" value="1.60" spread="0.25" lower_limit="1.30" upper_limit="2.11"/>
                    <measurement group_id="O4" value="1.86" lower_limit="1.60" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Famciclovir Pediatric Oral Formulation in Part B of the Study.</title>
        <description>A patient with multiple AEs within the primary system organ class is counted only once in total row.</description>
        <time_frame>Administered 2 times daily over 7 days</time_frame>
        <population>Includes 47 patients enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 to &lt; 2 Years</title>
          </group>
          <group group_id="O2">
            <title>2 to &lt;6 Years</title>
          </group>
          <group group_id="O3">
            <title>6 to &lt;13 Years</title>
          </group>
          <group group_id="O4">
            <title>13 to &lt;=18 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Famciclovir Pediatric Oral Formulation in Part B of the Study.</title>
          <description>A patient with multiple AEs within the primary system organ class is counted only once in total row.</description>
          <population>Includes 47 patients enrolled in Part B of the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders and administration site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, poisoning and procedural complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients in Parts A and B of the study who experienced adverse events. These AEs are presented by system organ class for each age group in the safety population.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A (Single-dose of Famciclovir)</title>
          <description>Includes 27 patients enrolled in Part A. Two adolescent patients (13 to 18 years) were enrolled in Part A of this study under an amendment to the protocol to include adolescent aged patients. The amendment was rescinded in compliance with an FDA Pediatric Written Request and no further adolescent aged patients were enrolled.</description>
        </group>
        <group group_id="E2">
          <title>Part B (Multiple-dose of Famciclovir)</title>
          <description>Includes 47 patients enrolled in Part B. Part B started only after pharmacokinetic (PK) data from Part A had been analyzed. One patient that participated in Part A of the study also participated in Part B.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

